Clinical trials evaluated plasma p-tau217 in individuals with Aβ pathology, implying its potential as an endpoint.
Our findings support that changes in plasma p-tau217 represent a robust endpoint for clinical trials targeting CU or CI individuals with Aβ pathology.
No takes yet. Share an insight, caveat, or question.
Ferreira et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: